---
title: "Preserved aerobic capacity after allogeneic HCT in an elite endurance runner"
id: "frontiers-in-immunology-16-case-report-running-through-transplant-preserved-aerobic-capacity-in-an-elite"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-case-report-running-through-transplant-preserved-aerobic-capacity-in-an-elite"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1940963"
published_at: "2026-11-13T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Preserved aerobic capacity after allogeneic HCT in an elite endurance runner
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-case-report-running-through-transplant-preserved-aerobic-capacity-in-an-elite
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1940963)
- **Published At:** 2026-11-13T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators reported a longitudinal case of a 54-year-old elite endurance runner who resumed structured treadmill exercise on Day +1 after matched-sibling **allogeneic HCT** for transformed lymphoma. - The participant recorded contemporaneous training logs (treadmill speed/grade, heart rate, RPE) that were aligned to transplant milestones, donor chimerism events, DLI, and immunosuppression changes. - Serial cardiopulmonary exercise tests (CPETs) were obtained independently: pre-HCT (5 months before), 7 months post-HCT, and a submaximal 20-month test; original reports and gas-exchange outputs were reviewed retrospectively. - Directly measured **VO2 peak** was 75.8 mL/kg/min pre-HCT and 71.5 mL/kg/min at 7 months post-HCT; the 20-month CPET was submaximal and did not yield a VO2 peak. - VT1 and VT2 values were estimated or determined per available data: VT1 ≈53.0 mL/kg/min pre-HCT, 48.0 at 7 months, 42.4 at 20 months; VT2 ≈66.0 and 59.9 mL/kg/min pre-HCT and 7 months, respectively. - During profound cytopenia (WBC nadir 0.04 ×10^9/L; platelets nadir 11 ×10^9/L) the runner performed daily moderate-intensity treadmill walking at ~60% HRR and RPE 4–6, with training restricted during platelet nadir. - The athlete progressed to running within 100 days, logged a 5K of 17:55 (Day +314) and a 10K of 41:00 (Day +340) while receiving prednisone plus cyclosporine for **cGvHD**. - Authors noted methodological heterogeneity across CPET reports (different labs, unavailable breath-by-breath data, and estimated thresholds from plots), which limited uniform reanalysis and constrained interpretation of maximality at some timepoints. - Data indicate that exceptional aerobic capacity and race-level endurance performance can be maintained through recovery from allogeneic HCT, including periods of corticosteroid-treated **cGvHD**, when structured training is continued; the report is a single-case observation and not a protocol-driven trial.
## Clinical Analysis & Structured Key Points
Frontiers | Case Report: Running through transplant: preserved aerobic capacity in an elite endurance athlete after allogeneic hematopoietic cell transplantation CASE REPORT article Front. Immunol. , 13 November 2026 Sec. Alloimmunity and Transplantation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1940963 Published in Frontiers in Immunology Alloimmunity and Transplantation 7 impact factor 11.3 citescore Editor & Reviewers Edited by C G Cynthia Giver Reviewed by G K Giorgos K. Sakkas S D Stefan De Smet Outline Figures and Tables Table 1 Serial cardiopulmonary exercise testing across the transplant course. View in article Table 2 Endurance performance and training milestones aligned with the post-transplant course. View in article CASE REPORT article Front. Immunol. , 13 November 2026 Sec. Alloimmunity and Transplantation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1940963 Case Report: Running through transplant: preserved aerobic capacity in an elite endurance athlete after allogeneic hematopoietic cell transplantation E K Emmanuel Katsanis 1,2,3,4,5 † * K M Kenneth Martin 6 R J Richard J. Simpson 1,2,5,7 † 1. Department of Pediatrics, University of Arizona, Tucson, AZ, United States 2. Department of Immunobiology, University of Arizona, Tucson, AZ, United States 3. Department of Medicine, University of Arizona, Tucson, AZ, United States 4. Department of Pathology, University of Arizona, Tucson, AZ, United States 5. The University of Arizona Cancer Center, Tucson, AZ, United States 6. Workoutcancer, Bend, OR, United States 7. School of Nutritional Sciences and Wellness, University of Arizona, Tucson, AZ, United States See more Article metrics View details Abstract Allogeneic hematopoietic cell transplantation (HCT) imposes profound hematologic, inflammatory, and immunologic stress, and survivors typically show reduced cardiorespiratory fitness that may be further compromised by chronic graft-versus-host disease (cGvHD) and corticosteroid therapy. Competitive, performance-oriented endurance training through these phases has not been described. We report the longitudinal clinical and training course of a 54-year-old elite endurance runner with previously treated Hodgkin lymphoma who resumed structured treadmill exercise on Day +1 after matched-sibling allogeneic peripheral blood stem cell transplantation for diffuse large B-cell lymphoma transformed from follicular lymphoma. Daily physiologic training data were aligned with transplant milestones, donor chimerism, donor lymphocyte infusions (DLI), and immunosuppression, and serial cardiopulmonary exercise testing was performed before and after HCT. The patient exercised through marrow aplasia and progressed to timed running within 100 days; he recorded a 5K of 17:55 (Day +314) and a 10K of 41:00 (Day +340), both during active cGvHD on prednisone plus cyclosporine. Directly measured peak oxygen uptake (VO 2 peak) was 75.8 mL/kg/min before HCT and 71.5 mL/kg/min at 7 months post-HCT. Oxygen uptake (VO 2 ) at the first ventilatory threshold (VT1) was 53.0, 48.0, and 42.4 mL/kg/min before HCT and at 7 and 20 months post-HCT, respectively. VO 2 at the second ventilatory threshold (VT2) was 66.0 and 59.9 mL/kg/min before HCT and at 7 months post-HCT, respectively. The 20-month assessment was submaximal; therefore, VO 2 peak was not determined. This case illustrates that exceptional aerobic capacity and high-level endurance performance can be maintained during recovery from allogeneic HCT, including during corticosteroid-treated cGvHD, with continued structured training. Introduction Allogeneic hematopoietic cell transplantation (HCT) represents one of the most physiologically demanding treatments in clinical medicine ( 1 – 3 ). Conditioning-related myelosuppression, profound cytopenias, mucosal injury, systemic inflammatory activation, and prolonged immune reconstitution collectively impose substantial metabolic and functional stress ( 1 , 4 , 5 ). Early post-transplant management typically prioritizes infection prophylaxis, transfusion support, electrolyte stabilization, and cautious mobilization. Exercise recommendations during this period are generally conservative and emphasize light ambulation or supervised rehabilitation ( 6 – 9 ). Although physical activity is encouraged in transplant recovery, the existing literature largely focuses on structured rehabilitation programs conducted at low intensity ( 2 , 10 – 12 ). Several supervised rehabilitation programs and trial protocols in HCT include moderate-intensity exercise during cytopenia ( 3 , 13 – 18 ). What has not been described is competitive, performance-oriented endurance training carried through marrow aplasia and through corticosteroid-treated chronic graft-versus-host disease (cGvHD), with concurrent objective physiologic and race-performance data aligned to transplant milestones and immunosuppressive management. Here we present the detailed longitudinal clinical and training course of a competitive 54-year-old endurance runner who resumed structured treadmill exercise beginning on Day +1 following allogeneic HCT. This report integrates transplant-related events, immune recovery, cGvHD treatment, and daily physiologic training data, including treadmill speed and grade, heart rate reserve (HRR), rating of perceived exertion (RPE), and race-level performance metrics. By aligning objective performance measures with the evolving transplant and immunosuppressive course, we provide a data-grounded account of functional capacity from the immediate post-transplant period through cGvHD management and recovery. Training data were recorded prospectively by the patient, while independently obtained cardiopulmonary exercise tests (CPETs) performed before and after transplantation were analyzed retrospectively. Both are described in the Methods. Methods Cardiopulmonary exercise testing The participant independently obtained graded CPETs from local exercise-testing laboratories before and after HCT; these assessments were not prescribed or prospectively standardized as part of the present case report. The pre-HCT assessment was conducted at the Human Biomechanics and Physiology Laboratory at High Point University (High Point, NC), and the 7- and 20-month post-HCT assessments were conducted at the National Institute for Fitness and Sport (Indianapolis, IN). Original test reports and available gas-exchange outputs were obtained retrospectively from the participant and subsequently reviewed by the authors. Although common physiological criteria were applied when identifying and interpreting the first (VT1) and second (VT2) ventilatory thresholds, differences in the format and completeness of the available data precluded uniform reanalysis of all three assessments using identical breath-by-breath processing and threshold-determination procedures. Where numerical data were unavailable, values were estimated from the graphical outputs and identified as such. The pre-HCT and 7-month post-HCT assessments were maximal graded exercise tests conducted to volitional exhaustion using a constant-speed protocol with 1-minute stages, beginning at 0% gradient, with gradient increased by 1% each minute. Speed was maintained at 16.1 km/h (10 mph) at both assessments. The 20-month assessment was intentionally submaximal and was performed at a constant gradient of 1.5%, beginning at 12.6 km/h (7.8 mph), with speed increased by 0.5 km/h (0.3 mph) every 3 minutes to a final speed of 14.5 km/h (9.0 mph). The test was terminated at an RPE of 7.5 on a 0–10 scale. All three assessments were performed on Woodway treadmills. Respiratory gas-exchange and heart-rate responses were recorded throughout each assessment. Because the assessments were independently obtained and the original records differed in technical detail, the metabolic cart models, gas-exchange averaging procedures, and complete calibration procedures were not recoverable for every assessment. Whether standardized verbal encouragement was provided, and the clinical criteria used to terminate each test, were likewise not documented in the available reports. Maximal tests were recorded as ending at volitional exhaustion. The pre-HCT report documented calibration of gas concentrations and flow before testing, including flow calibration using a 3-L syringe. For the two maximal assessments, peak oxygen uptake (VO 2 peak) was defined as the highest reported oxygen uptake (VO 2 ) attained during the test. These values are reported as VO 2 peak rather than maximal oxygen uptake (VO 2 max) because the available records did not consistently demonstrate conventional secondary criteria for establishing VO 2 max. The 20-month assessment was submaximal; therefore, VO 2 peak and VT2 were not determined, and its terminal heart rate and respiratory exchange ratio (RER) were not interpreted as maximal responses. VT1 was assessed through collective interpretation of the V-slope, excess-CO 2 , and ventilatory-equivalent methods, as described by Gaskill et al. ( 19 ) VT2 was identified as the onset of respiratory compensation, evidenced by a further increase in the ventilatory equivalent for oxygen (VE/VO 2 ) accompanied by an increase in the ventilatory equivalent for carbon dioxide (VE/VCO 2 ) ( 20 ). VT1 was identified during all three assessments, and VT2 during the first two assessments only. Two investigators experienced in exercise physiology and CPET interpretation independently assessed VT1 and VT2 retrospectively. Original laboratory threshold annotations and clinical-timepoint identifiers were removed before review. VT1 was accepted when at least two of the three methods demonstrated a concordant transition, and VT2 was identified using the respiratory-compensation criteria described above. Differences in the precise threshold location were resolved by joint review and consensus. Numerical 15-second gas-exchange data were available for the 7- and 20-month assessments; because numerical data were unavailable for the pre-HCT assessment, its thresholds were estimated from the original graphical output using the same physiological criteria. Body mass was recorded as 69.5 kg in the original report for each assessment. Whether body mass was measured contemporaneously on each test day could not be verified from the available retrospective records. The corresponding physiological values are reported in Table 1 . Table 1 CPET variable¶ 5 months pre-HCT 7 months post-HCT (Day +220) 20 months post-HCT† Body mass (kg) 69.5 69.5‡ 69.5 VT1§ VO 2 (L/min) 3.68 3.34 2.95 VO 2 (mL/kg/min) 53.0 48.0 42.4 VO 2 (% VO 2 peak) 69.9 67.1 NA Heart rate (bpm) NR 138 137 VT2§ VO 2 (L/min) 4.59 4.16 ND VO 2 (mL/kg/min) 66.0 59.9 ND VO 2 (% VO 2 peak) 87.1 83.8 NA Heart rate (bpm) NR 148 ND Peak/terminal exercise Measured VO 2 peak (L/min) 5.266 4.97 ND Measured VO 2 peak (mL/kg/min) 75.8 71.5 ND Peak/terminal heart rate (bpm) NR 163 163† Peak/terminal RER 1.06 0.92 0.89† Terminal RPE (0–10) NR NR 7.5† Serial cardiopulmonary exercise testing across the transplant course. † The 20-month assessment was a submaximal CPET terminated at an RPE of 7.5/10. Accordingly, VO 2 peak was not determined, and terminal heart rate and RER should not be interpreted as maximal responses. VT2 could not be determined with sufficient confidence at the 20-month assessment because the available gas-exchange responses did not consistently corroborate a discrete respiratory compensation point. VT1 could nevertheless be identified from the submaximal gas-exchange data. ‡ Body mass was recorded as 69.5 kg in the original test report at each assessment; whether it was measured on the day of each test or carried forward in the participant record could not be independently verified. § VT1 was identified using concordance among the V-slope, ventilatory-equivalent, and excess-CO 2 methods. VT2 was identified as the onset of respiratory compensation, evidenced by a further increase in VE/VO 2 accompanied by an increase in VE/VCO 2 . Because breath-by-breath data were unavailable for the pre-HCT assessment, its threshold values were estimated retrospectively from the available graphical output. ¶ The pre-HCT and 7-month maximal tests used a constant-speed treadmill protocol with 1-minute stages, beginning at 0% gradient and increasing by 1% each minute; speed was maintained at 16.1 km/h (10 mph) at both assessments. The 20-month submaximal test used a constant 1.5% gradient, beginning at 12.6 km/h (7.8 mph) and increasing by 0.5 km/h (0.3 mph) every 3 minutes to 14.5 km/h (9.0 mph). CPET, cardiopulmonary exercise testing; HCT, hematopoietic cell transplantation; NA, not applicable; ND, not determined; NR, not recoverable from the available report; RER, respiratory exchange ratio; RPE, rating of perceived exertion; VO 2 peak, peak oxygen uptake; VT1, first ventilatory threshold; VT2, second ventilatory threshold. Training data Longitudinal training data were obtained from detailed contemporaneous training logs maintained by the participant rather than reconstructed solely through retrospective recall. The logs included treadmill speed and gradient, exercise duration, heart rate, and RPE. Heart rate and treadmill workload were recorded during each training session using the participant’s heart-rate monitor and treadmill display; specific device models were not consistently documented. Perceived exertion was recorded using a 0–10 rating scale. HRR was calculated as the difference between peak and resting heart rate, and relative exercise intensity was expressed as [(exercise heart rate − resting heart rate)/(peak heart rate − resting heart rate)] × 100. The participant used the peak heart rate attained during his most recent maximal graded treadmill test to calculate HRR and prescribe subsequent training intensity. Resting heart rate was obtained from the value recorded by the participant in his contemporaneous training records. Log entries were cross-checked against transplant-center records for this report, and the two sources agreed. Case presentation Pre-transplant athletic background The patient was a highly accomplished endurance athlete with an exceptional competitive record prior to transplantation. He had achieved performances attained by only a small number of runners, including a sub-4-minute mile and a 2:10 marathon at ages 22 and 31, respectively. Although beyond his peak competitive years at the time of presentation, he continued to train at a high level. Structured sessions included repeated 800-meter intervals in the 2:12 to 2:17 range and 400-meter repetitions averaging 65 to 67 seconds. Treadmill workouts progressed to approximately 3:06 min/km (5:00 min/mile). He had a remote pre-transplant history of lower-limb stress fractures and no other comorbidity. Baseline cardiopulmonary exercise test Five months before HCT and one month before presentation, at age 54, he completed a graded maximal exercise test on a motorized treadmill with metabolic gas analysis, achieving a directly measured VO 2 peak of 75.8 mL/kg/min. VT1 and VT2 were retrospectively estimated from the available graphical output at approximately 53.0 mL/kg/min (69.9% of VO 2 peak) and 66.0 mL/kg/min (87.1% of VO 2 peak), respectively ( Table 1 ). Body mass recorded at this assessment was 69.5 kg, corresponding to an absolute VO 2 peak of 5.266 L/min. The test was terminated at volitional exhaustion, with a peak RER of 1.06. Peak heart rate and the presence or magnitude of a VO 2 plateau could not be recovered from the available report; accordingly, the result is reported as VO 2 peak rather than VO 2 max. Because numerical breath-by-breath data were unavailable, the threshold values should be interpreted as approximate. Diagnosis and transplantation Approximately three years before HCT, he was diagnosed with stage IIA Hodgkin lymphoma on an aortocaval lymph node biopsy and received six cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Ten months later, a biopsy of residual retroperitoneal lymphadenopathy showed grade 1–2 follicular lymphoma. Two years after that, he developed fatigue, night sweats, and recurrent low-grade fevers (B symptoms). PET imaging showed widespread hypermetabolic adenopathy, and biopsy of a 5-cm retroperitoneal mass confirmed diffuse large B-cell lymphoma arising from histologic transformation of the follicular lymphoma. After two cycles of R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin), repeat PET showed no active disease, but a pre-transplant bone marrow biopsy showed 10% involvement by follicular lymphoma. He then underwent matched sibling donor allogeneic peripheral blood stem cell transplantation from his 57-year-old brother. Reduced intensity conditioning consisted of alemtuzumab, fludarabine, and melphalan. Baseline organ function was normal, with a left ventricular ejection fraction of 68% and a forced expiratory volume in 1 second (FEV1) of 98% predicted. Graft-versus-host disease (GvHD) prophylaxis included alemtuzumab (administered within the conditioning regimen for in vivo T-cell depletion) and cyclosporine (CSA). Day 0 to Day +30, aplasia and early mobilization During the first month after HCT the patient experienced profound cytopenia, with a white blood cell (WBC) nadir of 0.04 ×10 9 /L (Day +9), platelet nadir of 11 ×10 9 /L (Day +9), and hemoglobin as low as 8.3 g/dL (Day +11). Despite these values he resumed structured treadmill exercise on Day +1 and performed near-daily moderate-intensity treadmill walking: sessions of at least 30 minutes at 6.0 to 6.4 km/h and 2% to 7% incline, at approximately 60% HRR, with RPE of 4 to 6 ( Table 2 ). On Day +27 he was briefly readmitted for non-neutropenic fever and chills; blood and urine cultures and chest radiography were negative, no infectious source was identified, and intravenous immunoglobulin was initiated for transplant-associated hypogammaglobulinemia. A chemotherapy-related sensory peripheral neuropathy involving the fingers and feet was present throughout this period. Body mass fell from 71.7 kg at the start of conditioning to a nadir of 66.4 kg on Day +24 and had recovered to 69.1 kg by Day +92 and 70.4 kg by Day +323, close to the pre-illness baseline of 69.4 kg. Exercise heart rate during this phase remained near 110 beats per minute, and no exaggerated tachycardia or orthostatic instability was recorded. Exercise was restricted to low-impact treadmill walking throughout the platelet nadir. The training log documents that treadmill walking continued on days when the platelet count was 11 to 47 ×10 9 /L, that weight-bearing treadmill walking was chosen in preference to cycling, and that sessions were omitted on Day +10 and intensity was capped while gastrointestinal symptoms persisted. C-reactive protein (CRP) was 38 mg/L early post-transplant. Table 2 Day post-HCT Session / event Result Peak HR (bpm) RPE Clinical context/immunosuppression Day +1 Resumed treadmill walking 30 min; 6.0–6.4 km/h (3.7–4.0 mph); 2–7% incline; ~60% HRR ~110 4–6 Aplasia (WBC nadir 0.04×10 9 /L on Day +9); cyclosporine Day +27 Brief hospitalization culture-negative febrile episode Engrafting; IVIG started for hypogammaglobulinemia Day +15 to +89 Incline interval progression 2–4% grade; 60–70% HRR 6–7 Hematologic recovery; CSA weaned Day +87 First sustained run 3 miles 160–170 Early immune reconstitution; post DLI-1 Day +94 5K 25:00 160 Early immune reconstitution Day +95 5K 23:51 Day +100 5K 23:00 163 6–8 Day +314 5K 17:55 166 9 Active cGvHD; prednisone 20 mg + CSA 25 mg Day +340 10K 41:00 157 Active cGvHD; prednisone + CSA 18–22 months up to 16.1 km/h (10.0 mph) Alternating prednisone 5/0 mg; stopped Endurance performance and training milestones aligned with the post-transplant course. HRR, heart rate reserve; RPE, rating of perceived exertion (0–10 scale); WBC, white blood cell count; DLI, donor lymphocyte infusion; CSA, cyclosporine; IVI
## Related Clinical Research

- [LGsig: Gene-Expression Classifier Integrating Genetics to Predict Therapy Response in DLBCL](https://medichelpline.com/clinical-feed/pubmed-42715516.md) (DOI: 10.1200/JCO-26-00451)
- [Composite Follicular Lymphoma and Mantle Cell Lymphoma: Single-Case Diagnostic Report](https://medichelpline.com/clinical-feed/pubmed-42967635.md) (DOI: 10.3760/cma.j.cn112151-20260322-00195)
- [Sintilimab plus R-CHOP vs DA-EPOCH-R in PMBCL — article content unavailable on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-sintilimab-plus-r-chop-versus-da-epoch-r-as-first-line-therapy-for-primary.md)
- [GAA as a Prognostic Biomarker and Therapeutic Target in Angioimmunoblastic T‑cell Lymphoma — Full](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-multi-omics-analysis-identifies-gaa-as-an-independent-poor-prognostic-biomarker.md)
- [Disseminated Trimethoprim/Sulfamethoxazole–Resistant Nocardiosis in a Renal Transplant Recipient](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-3-disseminated-trimethoprim-sulfamethoxazole-resistant-nocardiosis-in-renal.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.